Treatment of atherosclerosis with cholesterol ester transport protein mimotopes

Abstract

The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.

1 . Peptide consisting of at least one amino acid sequence selected from the group consisting of SYHATFL, TMAFPLN, HYHGAFL, EHHDIFL, SSLELFL, TGLSVFL, WMPSLFY, SMPWWFF, TMPLLFW, DTWPGLE, SMPPIFY, MPLWWWD, SMPNLFY, RMPPIFY, NPFEVFL, TLPNWFW, SMPLTFY, SFLDTLT, NFLKTLS, DFLRTLT, AFLDTLV, TFLSSLA, GFLDSLM, SPHPHFL, NFMSIGL, SQFLASL, SNFLKTL, TGFLATL, WSWPGLN, IAWPGLD, SKFMDTL, SDFLRAL, SMPMVFY, YEWVGLM, KGFLDHL, SANPRDFLETLF, RMFPESFLDTLW, TIYDSFLDSLAS, HQSDDKMPWWFF, KPYLLKDFLEAL, AMGPYDALDLFL, TWNPIESFLESL, YVWQDPSFTTFF, QYQTPLTFLEAL, RHISPATFLEAL, HTDSFLSTFYGD, YVWQDPSFTTFF, ADSTFTSFLQTL, GPVSIYADTDFL, DSNDTLTLAAFL, NGSPALSHMLFL, TDYDPMWVFFGY, IFPLDSQWQTFW, NESMPDLFYQPS, DWGDKYFSSFWN, VSAYNNV, WPLHLWQ, TPTHYYADFSQL, LPGHLIWDSLHY, LPQTHPLHLLED, IPYHHLVDQLHH, YPYHVQVDVLQN, IPSHHLQDSLQL, EYAHHTSLDLRQ, EPLHFRSDRIQA, ATPSHLIIDRAQ, APKHLYADMSQA, FKPAHVSIDWLQ, MPAHLSRDLRQS, NPKHYSIDRHQA, SPQHLTTDRAQA, TPFHFAQDSWQW, TPTHYYADFSQLLS, TPTHYYADFSQSLS, GTPTHYYADFSQLL, GTPTHYYADFSQSL, FGTPTHYYADFSQSLS, FGFPTHYYADFSQSLS, LPGHLIWDSLHY, LPGHLIWDSLHYL, LPGHLIWDSLHYLS, LPGHLIWDSLHSL, LPGHLIWDSLHSLS, GLPGHLIWDSLHYL, GLPGHLIWDSLHSL, FGLPGHLIWDSLHSLS, FGFPGHLIWDSLHSLS, LPQTHPLHLLED, IPYHHLVDQLHH, IPYHHLVDQLHLS, IPYHHLVDQLHSLS, FGIPYHHLVDQLHHLS, FGFPYHHLVDQLHSLS, YPYHVQVDVLQN, YPYHVQVDVLQNLS, YPYHVQVDVLQSLS, FGYPYHVQVDVLQNLS, FGFPYHVQVDVLQSLS, IPSHHLQDSLQL, IPSHHLQDSLQLLS, IPSHHLQDSLQSLS, GIPSHHLQDSLQLL, FGIPSHHLQDSLQLLS, FGFPSHHLQDSLQSLS, EYAHHTSLDLRQ, EPLHFRSDRIQA, EPLHFRSDRIQALS, EPLHFRSDRIQSLS, GEPLHFRSDRIQAL, FGEPLHFRSDRIQALS, FGFPLHFRSDRIQSLS, APKHLYADMSQA, APKHLYADMSQALS, APKHLYADMSQSLS, GAPKHLYADMSQAL, FGFPKHLYADMSQSLS, MPAHLSRDLRQS, MPAHLSRDLRQSL, MPAHLSRDLRQSLS, GMPAHLSRDLRQSL, FGFPAHLSRDLRQSLS, NPKHYSIDRHQA, TPFHFAQDSWQW, TPFHFAQDSWQWLS, TPFHFAQDSWQSLS, GTPFHFAQDSWQWL, FGFPFHFAQDSWQSLS, ACSFAYLYRC, ACFMGDKWVC, ACVLYPKAIC, ACYMGQQFVC, ACLTAYLHWC, ACTLFPVAYC, ACWLFPYAHC, ACKSINMWLC, ACQTINRWLC, FGFPEHLLVDFLQSLS, FGFPEHLLVDFLQSLS, FPEHLLVDFLQSL, AGFPEHLLVDFLQSLS, FAFPEHLLVDFLQSLS, FGAPEHLLVDFLQSLS, FGFAEHLLVDFLQSLS, FGFPAHLLVDFLQSLS, FGFPEALLVDFLQSLS, FGFPEHALVDFLQSLS, FGFPEHLAVDFLQSLS, FGFPEHLLADFLQSLS, FGFPEHLLVAFLQSLS, FGFPEHLLVDALQSLS, FGFPEHLLVDFAQSLS, FGFPEHLLVDFLASLS, FGFPEHLLVDFLQALS, FGFPEHLLVDFLQSAS, FGFPEHLLVDFLQSLA, FAFPAHLLVDFLQALA, AAFPAHLLADFLQALA, SPQHLTTDRAQA, SPQHLTTDRAQALS, SPQHLTTDRAQALS, GSPQHLTTDRAQAL, FGFPQHLTTDRAQSLS, FGFPQHLTTDWAQSLS, FGFPQHLTTDRLQSLS, FGFPQHLTTDWLQSLS, ATPSHLIIDRAQ, ATPSHLIIDRAQSLS, FGFPSHLIIDRAQSLS, FGFPSHLIIDWAQSLS, FGFPSHLIIDWLQSLS, FGFPSHLIIDWSQSLS, FATPSHLIIDWLQSLS, FKPAHVSIDWLQ, FKPAHVSIDWLQSLS, FGFPAHVSIDWLQSLS, AGFPAHVSIDWLQSLS, FAFPAHVSIDWLQSLS, FGAPAHVSIDWLQSLS, FGFAAHVSIDWLQSLS, FGFPAHVSADWLQSLS, FGFPAHVSIDWLQALS, FGFPAHVSIDWLQSLA, FAFPAHVSIDWLQALA, FGFAAHVSIDWLQSLS, FGFFAHVSIDWLQSLS, FGFPAHVSIRWLQSLS, FGFPAHVSIEWLQSLS, FGFPAHVSIDWLNSLS, FGFPAHVSIDWLHSLS, AGFPAHVSIDWLQSLS, PGFPAHVSIDWLQSLS, WGFPAHVSIDWLQSLS, FAFPAHVSIDWLQSLS, FGFPAHVSIDWLQSLS, FYFPAHVSIDWLQSLS, FDFPAHVSIDWLQSLS, FGAPAHVSIDWLQSLS, FGFPAHVSIDWLQLLS, FGFPAHVSIDWLQWLS, FGFPAHVSIDWLQNLS, FGFPAHVSIDWLQTLS, FGFPAHVSIDWLQYLS, FGFPAHVSIDWLQSIS, FGFPAHVSIDWLQSLT, FGFPAHVSIDWLQSLY, FAFPAHVSIDWLQALA, FGFPAHVSIDRAQSLS, FGFPTHVSIDWLQSLS, FGFPFHVSIDWLQSLS, FGFPAHISIDWLQSLS, FGFPAHIIIDWLQSLS, FGFPAHLTTDWLQSLS, FGFPAHVFIDWLQSLS, FGFPAHVYIDWLQSLS, FGFPAHVSLDWLQSLS, FGFPAHVSADWLQSLS, TPTHYYADFSQSLS, FGFPAHVSIDWSQSLS, FGFPAHVSIDFSQSLS, FGFPSHIIIDWLQSLS, FGFPSHLIIEWLQSLS, AAFPAHLLADAAQALA, AAFPAHAAADFLQALA, AAFAAHLLADFLQAAA, AAAPAHLLVDAAQAAA, FAFPAHVFIDWLQSLS; FGFPAHVFIDWLQALS, FGFPAHVFIDWLQSLA, GFPAHVFIDWLQSLS, FPAHVFIDWLQSLS, PAHVFIDWLQSLS, FAFPAHVFIDWLQALA, FGFPEHLFVDFLQSLS, FGFPAHVHIDWLQSLS, FGFPAHVPIDWLQSLS, FGFPSHLFIDWAQSLS, PGFPAHVFIDWLQLIT, PAHVYIDWLQSLS, FGFPAHVYIDWLQ, FGFPAHVFIDWLQ, DFGFPSHLIIDWLQSLS, DFGFPAHVFIDWLQSLN, PSHLIIDWLQ, PAHVFIDWLQ, DFGFPAHVTIDWLQSLN, DFGFPAHVLIDWLQSLN, FGFPAHVYIDWLQSLS, FGFPAHVFIDWLQSLN and FGFPAHVFIDWLQSLA. 
     
     
         2 . Pharmaceutical formulation comprising at least one peptide according to  claim 1 . 
     
     
         3 . Formulation according to  claim 2 , characterised in that the peptide is coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin).